Neuropeptide Y: cerebrovascular innervation and vasomotor effects in the cat

Neuropeptide Y-, substance P- and VIP-immunoreactive nerves in cat spleen in relation to autonomic vascular and volume control

Neuropeptide Y (NPY)-immunoreactive (IR) nerve fibres were found around both arteries and veins and in smooth muscle trabeculae of the cat spleen with the highest density on the arterial side. Considerably more tyrosine hydroxylase (TH)- and dopamine-beta-hydroxylase (DBH)-positive than NPY-IR nerves were seen in the trabeculae and splenic capsule. The NPY-IR nerves in the spleen most likely originated in the coeliac ganglion, since (1) splanchnic nerve sectioning did not change the splenic NPY-IR nerves, (2) most neurones in the coeliac ganglion were NPY-IR, as well as DBH- and TH-positive, and (3) NPY-IR was transported axonally from the coeliac ganglion towards the spleen via the splenic nerve. Local NPY infusion in the isolated, blood-perfused cat spleen caused a marked increase in splenic vascular resistance and a small volume reduction. NA caused a comparatively larger reduction in splenic volume than NPY in addition to vasoconstriction. VIP-IR cell bodies in the coeliac ganglion were NPY- and TH-negative. VIP-IR nerves were seen both around the splenic artery and vein as well as around arterioles and within venous trabeculae of the spleen. VIP infusion caused reduction of splenic perfusion pressure (i.e. vasodilation) as well as an increase in splenic volume. Substance P-IR nerves, most likely of splanchnic afferent origin, were present in the coeliac ganglion around the splenic artery and arterioles of the spleen. Infusion of substance P induced marked reduction in perfusion pressure and a reduction in splenic volume. Enkephalin-immunoreactive nerves of splanchnic origin surrounded some TH- and NPY-positive, coeliac ganglion cells. It is concluded that several vasoactive peptides are located in splenic nerves. NPY is present in noradrenergic neurones and causes mainly increased vascular resistance. VIP occurs in non-adrenergic neurones of sympathetic origin and induces vasodilation and relaxation of the capsule. Finally, substance P is present in peripheral branches of spinal afferent nerves and causes vasodilation and capsule contraction. Stimulation of the splenic nerves may thus release several vasoactive substances in addition to noradrenaline, exerting a variety of actions.

Effects of cholecystokinin octapeptide on pial arteriolar diameter

The effects of the perivascular microapplication of sulphated cholecystokinin octapeptide (CCK-8) on pial arteriolar calibre have been examined in anaesthetised cats using a video-display image-splitting technique. The microinjection of CCK-8 (10(-7) M) in the injectate did not modify the constriction or dilatation of pial arterioles provoked by the perivascular microinjection of alkalotic (pH 7.45) or acidic (pH 6.8) artificial CSFs, respectively. Thus, although CCK-8-immunoreactive neuronal processes are known to be associated with cortical blood vessels, CCK-8 appears to have minimal vasomotor effects on pial vessels.

Lack of specific (3H) prazosin binding sites in dog and rabbit cerebral arteries

In order to explore the characteristics of alpha adrenergic receptors on cerebrovascular smooth muscle, specific binding sites for the alpha 1 adrenergic ligand, (3H) prazosin, were studied in blood vessel homogenates. No specific (3H) prazosin binding was found in either rabbit or dog cerebral arteries, but specific binding was demonstrated in the rabbit saphenous and ear arteries. In the ear artery 3H-prazosin binding was saturable with a Kd of 0.51 +/- 0.20 nM and a Bmax of 89 +/- 29 fmoles/mg protein. To confirm the adequacy of our membrane preparation, homogenates of both dog and rabbit cerebral arteries showed saturable specific binding with two different ligands: one for muscarinic receptors, [3H](-) quinuclidinyl benzilate (QNB) and one for alpha 2 adrenergic receptors, (3H) yohimbine. The results of these studies demonstrate a lack of alpha 1 adrenergic receptors on cerebral blood vessels, confirming functional studies showing only a weak contractile response to norepinephrine.

Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels

The contractile effect of neuropeptide Y (NPY) was tested on isolated segments of basilar artery, central ear artery, gastro-epiploic artery and vein, and femoral artery and vein from the rabbit. At 30 nM NPY did not evoke vasoconstriction; at 300 nM NPY evoked a weak and variable response. NPY greatly potentiated the response of the gastro-epiploic and femoral arteries to noradrenaline without affecting the maximum response. As tested on the gastro-epiploic artery NPY was effective at concentrations of 1 nM and higher. As tested on the femoral artery the potentiating effect of 30 nM NPY on noradrenaline-evoked contractions was apparent immediately and 30 min after the application of NPY, but not after one hour. NPY (30 nM) potentiated the contractile response to noradrenaline and histamine but not to 5-hydroxytryptamine or high K+. The response to histamine was augmented in both arteries and veins, whereas the response to noradrenaline was enhanced in arteries but not in veins. NPY failed to potentiate the prostaglandin F2 alpha-evoked contraction except in the gastro-epiploic vein.

Presence of neuropeptide Y in human circle of Willis and its possible role in cerebral vasospasm

Neuropeptide Y (NPY) has been demonstrated in the human circle of Willis by specific radioimmunoassay. Concentrations were similar in cadaver and peroperative specimens. NPY concentrations were highest around the basilar bifurcation (2.9 +/- 1.0 pmol/g), anterior cerebral artery (2.7 +/- 0.5 pmol/g), and carotid trifurcation (2.4 +/- 0.6 pmol/g). Concentrations were lowest in the basilar artery (1.0 +/- 0.4 pmol/g). Intracarotid administration of NPY (50 pmol to 2 nmol) to rats reduced mean cerebral cortical blood flow by 40-98%. This vasoconstriction lasted for at least 2 h. These findings suggest that NPY may be involved in the cerebral vasospasm which follows subarachnoid haemorrhage and in the maintenance of normal vascular tone.

Distribution of FMRF-NH2-like immunoreactivity in rat and cat area postrema

The distribution of FMRF-NH2-like immunoreactivity, visualized with immunohistochemical techniques, was plotted in a range from very dense to none. The rat area postrema had differential immunostaining with the greatest amounts occurring at its ventral and ventrolateral borders by the nucleus of the solitary tract. Immunoreactive cell bodies were located mainly in this region. Throughout the central region of the rat area postrema scattered immunostaining was consistently observed. The cat area postrema had a different, greater, and more complex pattern of immunostaining than the rat. Very dense to dense accumulations of immunostaining occurred in the ventromedial region of the area postrema bordering the solitary tract and dorsal vagal nuclei, while the central region possessed scattered amounts of immunoreactivity. Following colchicine treatment, no visible FMRF-NH2-like immunoreactive cell bodies were observed in the cat area postrema.

Interaction of peptides present in perivascular nerves on the smooth muscle of cat cerebral arteries and on the stimulation-evoked efflux of 3H-noradrenaline

Studies have been performed using isolated segments of the middle cerebral artery of the cat to determine whether noradrenaline (NA), neuropeptide Y (NPY), avian pancreatic polypeptide (APP), substance P (SP), vasoactive intestinal polypeptide (VIP) and gastrin releasing peptide (GRP) have effects that involve pre- and/or postsynaptic mechanisms. NA, clonidine, NPY and APP produced concentration-dependent contractions of cerebral artery segments, whereas SP and VIP induced relaxation of prostaglandin F2 alpha-contracted arteries. GRP, in the concentrations tested, (up to 2 X 10(-7)M) had no vasomotor activity. The alpha 2-adrenoreceptor agonist clonidine (10(-8) and 10(-6)M) produced a reduction in the field stimulation-evoked release of 3H-NA previously incorporated into the noradrenergic transmitter pool of the arteries, whereas the alpha 2-adrenoreceptor antagonist rauwolscine (10(-8) and 10(-6)M) resulted in increases in 3H-NA release. However, none of the peptides caused any significant change of the stimulation-evoked fractional release of 3H-NA. The results suggest that NPY, APP, SP and VIP have postjunctional effects in cat cerebral arteries and, in the concentrations tested do not affect stimulation-evoked NA release.